These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
59 related articles for article (PubMed ID: 9630051)
1. Conversion from Sandimmun to Neoral in stable pediatric renal transplant recipients. Hoyer PF; Bökenkamp A Pediatr Nephrol; 1998 Apr; 12(3):260-1. PubMed ID: 9630051 [No Abstract] [Full Text] [Related]
2. Impact of late conversion from C0 to C2 monitoring of microemulsified cyclosporine in pediatric living donor liver transplant recipients. Takatsuki M; Chen CL; Chen YS; Wang CC; Lin CC; Yang CH; Yong CC; Liu YW Clin Transplant; 2004 Dec; 18(6):694-9. PubMed ID: 15516246 [TBL] [Abstract][Full Text] [Related]
3. Cyclosporin A (Neoral) in pediatric organ transplantation. Neoral Pediatric Study Group. Hoyer PF Pediatr Transplant; 1998 Feb; 2(1):35-9. PubMed ID: 10084758 [TBL] [Abstract][Full Text] [Related]
4. Sandimmun-to-Neoral conversion in stable pediatric kidney transplant recipients. Kelles A; Herman J; Tjandra-Maga TB; Van Damme-Lombaerts R Transplant Proc; 1998 Aug; 30(5):1995-6. PubMed ID: 9723366 [No Abstract] [Full Text] [Related]
5. How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients? Gaspari F; Perico N; Pisoni R; Anedda MF; Signorini O; Caruso R; Gotti E; Remuzzi G Clin Transplant; 1998 Oct; 12(5):379-90. PubMed ID: 9787945 [TBL] [Abstract][Full Text] [Related]
6. Six-month clinical outcome of cyclosporine microemulsion formulation (Sigmasporin Microral) in stable renal transplant patients previously maintained on sandimmun neoral. Al Wakeel JS; Shaheen FA; Mathew MC; Abou Zeinab HM; Al Alfi A; Tarif NM; Al Mousawi MS; Mahmoud TS; Alorrayed AS; Fagir EA; Dham RS; Shaker DS Transplant Proc; 2008 Sep; 40(7):2245-51. PubMed ID: 18790205 [TBL] [Abstract][Full Text] [Related]
7. Comparison of the efficacy and safety of Consupren solution and Sandimmun Neoral solution, 50 ml in stable heart transplant patients. Toman J; Spinarová L; Krejcí J; Hude P; Kopecná E; Kamarád V Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2002 Dec; 146(2):87-90. PubMed ID: 12572904 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic equivalence and mg:mg switch ability of a generic cyclosporine microemulsion formulation (Sigmasporin Microral) in stable renal transplant patients maintained on Sandimmun Neoral. Al Wakeel JS; Shaheen FA; Mathew MC; Abouzeinab HM; Al Alfi A; Tarif NM; Al Mousawi MS; Mahmoud TS; Alorrayed AS; Fagir EA; Dham RS; Shaker DS Transplant Proc; 2008 Sep; 40(7):2252-7. PubMed ID: 18790206 [TBL] [Abstract][Full Text] [Related]
9. Three-years experience with Neoral C2 monitoring adjusted to a target range of 500-600 ng/ml in long-term renal transplant recipients receiving dual immunosuppressive therapy. Carstens J Scand J Urol Nephrol; 2008; 42(3):286-92. PubMed ID: 18432535 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic conversion study of a new cyclosporine formulation in stable adult renal transplant recipients. Perlík F; Masri MA; Rost M; Kamarád V Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Dec; 149(2):309-13. PubMed ID: 16601778 [TBL] [Abstract][Full Text] [Related]
14. An open multicenter trial of conversion from Sandimmun to Neoral in stable kidney-transplant patients. Hourmant M; Antoine C; Bayle F; Bedrossian J; Berthoux F; Cassuto E; Chalopin JM; Charpentier B; Deteix P; Durand D; Hurault de Ligny B; Kessler M; Kreis H; Lang P; Lebranchu Y; Leroux-Robert C; Moulin B; Mourad G; Noël C; Olmer M; Potaux L; Pouteil-Noble C; Pruna A; Sraër JD; Soulillou JP Transplant Proc; 1997 Aug; 29(5):2313-4. PubMed ID: 9270741 [No Abstract] [Full Text] [Related]
15. [Passage from sandimmun to neoral in kidney transplantation in children]. Broyer M; Maisin A; Guest G; Baudouin V; Charbit M; Reigneau O; Loirat C Arch Pediatr; 1999 Oct; 6(10):1066-9. PubMed ID: 10544781 [TBL] [Abstract][Full Text] [Related]
16. Conversion from tacrolimus to cyclosporine microemulsion therapy in liver transplant recipients. Ogino S; Hashikura Y; Katsuyama Y; Ikegami T; Nakazawa Y; Urata K; Terada M; Miyagawa S; Kawasaki S Transplant Proc; 2004 Mar; 36(2 Suppl):299S-301S. PubMed ID: 15041357 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, efficacy, and safety of Iminoral compared with Neoral in healthy volunteers and renal transplant recipients. Sayyah M; Argani H; Pourmand GR; Amini H; Ahmadiani A Transplant Proc; 2007 May; 39(4):1214-8. PubMed ID: 17524936 [TBL] [Abstract][Full Text] [Related]
18. Experience with conversion from Sandimmun to Neoral cyclosporine and the correlation of C2 levels with renal function. Konstadinidou I; Boletis JN Transplant Proc; 2004 Mar; 36(2 Suppl):163S-166S. PubMed ID: 15041329 [TBL] [Abstract][Full Text] [Related]
19. A review of absorption characteristics of microemulsion cyclosporine products over the last 2 years in Indian subjects. Singh S; Sharma DR J Indian Med Assoc; 1999 Mar; 97(3):114-7. PubMed ID: 10652912 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery. Banner NR; David OJ; Leaver N; Davis J; Breen J; Johnston A; Yacoub MH Transpl Int; 2002 Dec; 15(12):649-54. PubMed ID: 12478413 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]